eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
SCImago Journal & Country Rank

3/2018
vol. 10
 
Share:
Share:
more
 
 
abstract:
Review paper

Brachytherapy boost after chemoradiation in anal cancer: a systematic review

Rezarta Frakulli, Milly Buwenge, Silvia Cammelli, Gabriella Macchia, Eleonora Farina, Alessandra Arcelli, Martina Ferioli, Lorenzo Fuccio, Luca Tagliaferri, Andrea Galuppi, Giovanni P. Frezza, Alessio G. Morganti

J Contemp Brachytherapy 2018; 10, 3: 246–253
Online publish date: 2018/06/29
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Radio-chemotherapy (RCT) is the primary treatment of anal cancer (AC). However, the role and the optimal total dose of a radiation boost is still unclear. No randomized controlled trials nor systematic reviews have been performed to analyze the efficacy of brachytherapy (BRT) as boost in AC. Therefore, we performed this systematic review based on PRISMA methodology to establish the role of BRT boost in AC.

A systematic search of the bibliographic databases: PubMed, Scopus, and Cochrane library from the earliest possible date through January 31, 2018 was performed. At least one of the following outcomes: local control (LC), loco-

regional control (LRC), overall survival (OS), disease-free survival (DFS), or colostomy-free survival (CFS) had to be present for inclusion in this systematic review in patients receiving a BRT boost. Data about toxicity and sphincter function were also included.

Ten articles fulfilled the inclusion criteria. All the studies had retrospective study design. All studies were classified to provide a level of evidence graded as 3 according to SIGN classification. Median 5-year LC/LRC, CFS, DFS, and OS were: 78.6% (range, 70.7-92.0%), 76.1% (range, 61.4-86.4%), 75.8% (range, 65.9-85.7%), and 69.4% (63.4-82.0%), respectively. The reported toxicities were acceptable.

RCT is the treatment cornerstone in AC. High-level evidences from studies on BRT boost in AC are lacking. Further studies should investigate: efficacy of BRT boost in comparison to no boost and to external beam boost, patients who can benefit from this treatment intensification, and optimal radiation dose.
keywords:

anal cancer, brachytherapy boost, systematic review

references:
Jemal A, Simard EP, Dorell C et al. Annual report to the nation on the status of cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013; 105: 175-201.
Boman BM, Moertel CG, O’Connell MJ et al. Carcinoma of the anal canal. A  clinical and pathologic study of 188 cases. Cancer 1984; 54: 114-125.
Greenall MJ, Quan SH, Urmacher C et al. Treatment of epidermoid carcinoma of the anal canal. Surg Gynecol Obstet 1985; 161: 509-517.
Dougherty BG, Evans HL. Carcinoma of the anal canal: A  study of 79 cases. Am J Clin Pathol 1985; 83: 159-164.
Nigro ND, Vaitkevicius VK, Considine B Jr. Combined therapy for cancer of the anal canal: A  preliminary report. Dis Colon Rectum 1974; 17: 354-356.
Nigro ND, Seydel HG, Considine B et al. Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer 1983; 51: 1826-1829.
http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#anal. Accessed: 31 January 2018.
Glynne-Jones R, Nilsson PJ, Aschele C et al. Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol 2014; 40: 1165-1176.
Hutton B, Salanti G, Caldwell DM et al. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med 2015; 162: 777-784.
http://www.ncbi.nlm.nih.gov/pubmed. Accessed: 31 January 2018.
http://www.scopus.com/. Accessed: 31 January 31 2018.
http://www.cochranelibrary.com/. Accessed: 31 January 2018.
http://www.sign.ac.uk/. Accessed: 15 December 2017.
Papillon J, Montbarbon JF. Epidermoid carcinoma of the anal canal. A  series of 276 cases. Dis Colon Rectum 1987; 30: 324-333.
Sandhu AP, Symonds RP, Robertson AG et al. Interstitial iridium-192 implantation combined with external radiotherapy in anal cancer: ten years’ experience. Int J Radiat Oncol Biol Phys 1998; 40: 575-581.
Weber DC, Kurtz JM, Allal AS. The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy. Int J Radiat Oncol Biol Phys 2001; 50: 675-680.
Chapet O, Gerard JP, Riche B et al. Prognostic value of tumor regression evaluated after first course of radiotherapy for anal canal cancer. Int J Radiat Oncol Biol Phys 2005; 63: 1316-1324.
Doniec JM, Schniewind B, Kovács G et al. Multimodal therapy of anal cancer added by new endosonographic-guided brachytherapy. Surg Endosc 2006; 20: 673-678.
Bruna A, Gastelblum P, Thomas L et al. Treatment of squamous cell anal canal carcinoma (SCACC) with pulsed dose rate brachytherapy: a  retrospective study. Radiother Oncol 2006; 79: 75-79.
Hannoun-Levi JM., Ortholan C, Resbeut M et al. High-dose split-course radiation therapy for anal cancer: outcome analysis regarding the boost strategy (CORS-03 study). Int J Radiat Oncol Biol Phys 2011; 80: 712-720.
Lestrade L, De Bari B, Pommier P et al. Role of brachytherapy in the treatment of cancers of the anal canal. Long-term follow-up and multivariate analysis of a  large monocentric retrospective series. Strahlenther Onkol 2014; 190: 546-554.
Gryc T, Ott O, Putz F et al. Interstitial brachytherapy as a  boost to patients with anal carcinoma and poor response to chemoradiation: Single-institution long-term results. Brachytherapy 2016; 15: 865-872.
Cordoba A, Escande A, Leroy T et al. Low-dose-rate interstitial brachytherapy boost for the treatment of anal canal cancers. Brachytherapy 2017; 16: 230-235.
Welton ML, Lambert R, Bosman FT. Tumors of the Anal Canal. In: Bosmqan FT, Carneiro F, Hruban RH, Theise ND (eds.). WHO Classification of tumors of the Digestive System. IARC, Lyon 2010; 183-193.
Pierquin B, Dutreix A, Paine CH et al. The Paris system in interstitial radiation therapy. Acta Radiol Oncol Radiat Phys Biol 1978; 17: 33-48.
Womack NR, Morrison JF, Williams NS. Prospective study of the effects of postanal repair in neurogenic faecal incontinence. Br J Surg 1988; 75: 48-52.
UKCCCR. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996; 348: 1049-1054.
Bartelink H, Roelofsen F, Eschwege F et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a  phase III randomized trial of the European organization for research and treatment of cancer radiotherapy and gastrointestinal cooperative groups. J Clin Oncol 1997; 15: 2040-2049.
Gunderson LL, Winter KA, Ajani JA et al. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol 2012; 30: 4344-4351.
Sodergren SC, Vassiliou V, Dennis K et al. Systematic review of the quality of life issues associated with anal cancer and its treatment with radiochemotherapy. Support Care Cancer 2015; 23: 3613-3623.
James RD, Glynne-Jones R, Meadows HM et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a  randomised, phase 3, open-label, 2x2 factorial trial. Lancet Oncol 2013; 14: 516-524.
Peiffert D, Tournier-Rangeard L, Gérard JP et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 Trial. J Clin Oncol 2012; 30: 1941-1948.
Saarilahti K, Arponen P, Vaalavirta L et al. The effect of intensity-modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer. Radiother Oncol 2008; 87: 383-90.
Widder J, Kastenberger R, Fercher E et al. Radiation dose associated with local control in advanced anal cancer: Retrospective analysis of 129 patients. Radiother Oncol 2008; 87: 367-375.
Falk AT, Claren A, Benezery K et al. Interstitial high dose rate brachytherapy as boost for anal canal cancer. Radiat Oncol 2014; 9: 240-241.
Tagliaferri L, Manfrida S, Barbaro B et al. MITHRA – multi­ parametric MR/CT image adapted brachytherapy (MR/CT-IABT) in anal canal cancer: a  feasibility study. J Contemp Brachytherapy 2015; 7: 336-345.
 
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe